Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland (2023)

First Author: Drysdale M

Attributed to: Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II) funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2023.06.09.23291195

Publication URI: http://dx.doi.org/10.1101/2023.06.09.23291195

Type: Preprint